Michal Oleksiejczuk made his UFC debut late last year at UFC 219, picking up a unanimous decision win over Khalil Rountree.
Oleksiejczuk has now been notified of a potential violation by the United States Anti-Doping Agency (USADA) from an in-competition sample collected in line with UFC 219.
The UFC issued the following statement on the matter:
The UFC organization was notified today that the U.S. Anti-Doping Agency (USADA) informed Michal Oleksiejczuk of a potential Anti-Doping Policy violation stemming from an in-competition sample collected in conjunction with his recent bout against Khalil Roundtree at UFC 219 in Las Vegas, Nevada on December 30, 2017.
USADA, the independent administrator of the UFC Anti-Doping Policy, will handle the results management and appropriate adjudication of this case involving Oleksiejczuk, as it relates to the UFC Anti-Doping Policy and future UFC participation. Because the Nevada Athletic Commission was the regulatory body overseeing the fight in Las Vegas and has licensing jurisdiction over Oleksiejczuk, USADA will work to ensure that the Nevada Athletic Commission has the necessary information to determine its proper judgment of Oleksiejczuk’s potential anti-doping violation. Additional information will be provided at the appropriate time as the process moves forward.
Since this is the first potential drug test failure for the fighter, possible punishments include the UFC 219 fight result being overturned to a no contest and a suspension.
While the UFC has commented on the situation, nothing has been said yet by Oleksiejczuk or his representatives.